EGFR and non-small cell lung carcinoma: Currently, epidermal growth factor (EGF) receptor tyrosine kinase inhibitors (EGFR‐TKIs), such as gefitinib, are the primary treatment for advanced NSCLC patients with EGFR mutations.136